News >

Trastuzumab Biosimilar Demonstrates Equivalence to Reference Product in HER2-Positive Breast Cancer

Wayne Kuznar
Published: Tuesday, Jun 05, 2018

Hans-Christian Kolberg, MD

Hans-Christian Kolberg, MD
The pathologic complete response (pCR) rate associated with the trastuzumab (Herceptin) biosimilar ABP 980 was equivalent to that of reference trastuzumab based on central laboratory evaluation in patients with HER2-positive early breast cancer enrolled in the phase III LILAC study.1

Amgen issued a brief statement May 31 announcing that it had received a compete response letter from the FDA for ABP 980.2 The letter means that the agency has rejected the biologics license application Amgen and its partner Allergan submitted in July 2017.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication